Status:
COMPLETED
AZD8330 First Time in Man in Patients With Advanced Malignancies
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies
Eligibility Criteria
Inclusion
- Cancer which is refractory to standard therapies, or no therapies exist;
Exclusion
- Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;
- Hasn't participated in investigation drug study within 30 days;
- Brain metastases/spinal cord compression unless treated and stable,
- Off steroids/anticonvulsants.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00454090
Start Date
March 1 2007
End Date
March 1 2011
Last Update
August 24 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States
2
Research Site
Houston, Texas, United States
3
Research Site
Oslo, Norway